Strategies to manage antifungal drug resistance

Bibliography

• Dupont B, Crewe Brown HH, Westermann K, Mycoses in AIDS. Med Mycol 2000;38(Suppl 1):259-67
   PubMedGoogle Scholar
• Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007;45:305-20
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010;50:1091-100
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003;3:772-85
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Kaufman D, Edwards JR, Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995 – 2004. Pediatrics 2006;117:1680-7
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7
   PubMed Web of Science ®Google Scholar
• Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17
   PubMed Web of Science ®Google Scholar
• Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 2003;6:197-218
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-8
   PubMed Web of Science ®Google Scholar
• Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005;27:657-73
   PubMed Web of Science ®Google Scholar
• Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis 2008;46:1426-33
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 2007;10:436-40
   PubMed Web of Science ®Google Scholar
• Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 2005;37:195-9
   PubMed Web of Science ®Google Scholar
• Brazier JS. Clostridium difficile: from obscurity to superbug. Br J Biomed Sci 2008;65:39-44
   PubMed Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GH, Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009;9:789-95
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46:120-8
   PubMed Web of Science ®Google Scholar
• McClenny NB, Fei H, Baron EJ, Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother 2002;46:1325-8
   PubMed Web of Science ®Google Scholar
• White TC, Holleman S, Dy F, Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002;46:1704-13
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, Results from the ARTEMIS DISK Global Anifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009;47:117-23
   PubMed Web of Science ®Google Scholar
• Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006;42:938-44
   PubMed Web of Science ®Google Scholar
• Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007;10:121-30
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Chua DJ, Tomada JR, Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 2010;54:2225-7
   PubMed Web of Science ®Google Scholar
• Pfeiffer CD, Garcia-Effron G, Zaas AK, Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010;48:2373-80
   PubMed Web of Science ®Google Scholar
• Sun HY, Singh N. Characterization of breakthrough invasive mycoses in echinocandin recipients: an evidence-based reviews. Int J Antimicrob Agents 2010;35:211-18
   PubMed Web of Science ®Google Scholar
• Kabbara N, Lacroix C, Peffault de Latour R, Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008;93:639-40
   PubMedGoogle Scholar
• Sipsas NV, Lewis RE, Tarrand J, Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001 – 2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009;115:4745-52
   PubMed Web of Science ®Google Scholar
• Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008;56:126-9
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006;107:2888-97
   PubMed Web of Science ®Google Scholar
• Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008;112:2309-12
   PubMed Web of Science ®Google Scholar
• CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard – third edition (M27-A3). Clinical and Laboratory Standards Institute (CLSI), Wayne, PA; 2008
   Google Scholar
• EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008;14:398-405
   PubMed Web of Science ®Google Scholar
• CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard – second ddition (M38-A2). Clinical and Laboratory Standards Institute (CLSI), Wayne, PA; 2008
   Google Scholar
• ESCMID SoASTAot, (EUCAST) ECfAST. EUCAST Definitive Document E.DEF 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. 2008
   Google Scholar
• Lass-Florl C, Mayr A, Perkhofer S, Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2008;52:3637-41
   PubMed Web of Science ®Google Scholar
• Canton E, Espinel-Ingroff A, Peman J. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev Anti Infect Ther 2009;7:107-19
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-9
   PubMed Web of Science ®Google Scholar
• Baddley JW, Marr KA, Andes DR, Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009;47:3271-5
   PubMed Web of Science ®Google Scholar
• Vos MC, Endtz HP, Horst-Kreft D, Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures. J Clin Microbiol 2006;44:1111-14
   PubMedGoogle Scholar
• Benet T, Nicolle MC, Thiebaut A, Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis 2007;45:682-6
   PubMed Web of Science ®Google Scholar
• Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009;47:1942-6
   PubMed Web of Science ®Google Scholar
• Breger J, Fuchs BB, Aperis G, Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 2007;3:e18
   PubMed Web of Science ®Google Scholar
• Meyer V. A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological value. Appl Microbiol Biotechnol 2008;78:17-28
   PubMed Web of Science ®Google Scholar
• Martinez LR, Mihu MR, Han G, The use of chitosan to damage Cryptococcus neoformans biofilms. Biomaterials 2010;31:669-79
   PubMedGoogle Scholar
• Wang J, Wu J. Antifungal activity of 25-azalanosterol against Candida species. Eur J Clin Microbiol Infect Dis 2008;27:1131-6
   PubMedGoogle Scholar
• Vale-Silva LA, Goncalves MJ, Cavaleiro C, Antifungal activity of the essential oil of thymus x viciosoi against Candida, Cryptococcus, Aspergillus and Dermatophyte species. Planta Med 2010;76(9):882-8
   PubMedGoogle Scholar
• Liu L, Xu K, Wang H, Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009;4:457-63
   PubMed Web of Science ®Google Scholar
• Wang H, Xu K, Liu L, The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials 2010;31:2874-81
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50:291-322
   PubMed Web of Science ®Google Scholar
• Bicanic T, Wood R, Bekker LG, Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005;5:530-1
   PubMed Web of Science ®Google Scholar
• Pappas PG, Chetchotisakd P, Larsen RA, A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009;48:1775-83
   PubMed Web of Science ®Google Scholar
• Harrison TS. Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis. Clin Infect Dis 2009;48:1784-6
   PubMedGoogle Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003;37(Suppl 3):S188-224
   PubMedGoogle Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006;20:711-27, viii
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21
   PubMed Web of Science ®Google Scholar
• Schabereiter-Gurtner C, Selitsch B, Rotter ML, Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens. J Clin Microbiol 2007;45:906-14
   PubMed Web of Science ®Google Scholar
• de Pauw BE, Patterson TF. Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005;41(Suppl 6):S377-80
   PubMedGoogle Scholar
• Matsue K, Uryu H, Koseki M, Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006;42:753-7
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Bennett CL, Yarnold PR, Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39:425-9
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31
   PubMed Web of Science ®Google Scholar
• Dignan FL, Evans SO, Ethell ME, An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009;44:51-6
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51
   PubMed Web of Science ®Google Scholar
• de Pauw BE, Donnelly JP. Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? Clin Infect Dis 2009;48:1052-4
   PubMed Web of Science ®Google Scholar
• Perfect JR. Antifungal prophylaxis: to be or not to be, that is still the question. J Invasive Fungal Infect 2007;1:2-3
   Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L, Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-8
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dodds Ashley E, Drew R. Design of aerosolized amphotericin B formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis 2004;39(Suppl 4):S207-10
   PubMedGoogle Scholar
• Perfect JR. Aerosolized antifungal prophylaxis: the winds of change? Clin Infect Dis 2008;46:1409-11
   PubMedGoogle Scholar
• Slavin MA, Osborne B, Adams R, Efficacy and safety prophylaxis for fungal infections after marrow transplantation – a prospective, randomized double-blind study. J Infect Dis 1995;171:1545-52
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2005-61
   PubMedGoogle Scholar
• Cornely OA, Maertens J, Winston DJ, Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Kantarjian H. Antifungal prophylaxis in patients with hematological cancers. J Invasive Fungal Infect 2007;1:10-6
   Google Scholar
• Segal BH, Kwon-Chung J, Walsh TJ, Immunotherapy for fungal infections. Clin Infect Dis 2006;42:507-15
   PubMed Web of Science ®Google Scholar
• Roilides E, Farmaki E. Granulocyte colony-stimulating factor and other cytokines in antifungal therapy. Clin Microbiol Infect 2001;7(Suppl 2):62-7
   PubMedGoogle Scholar
• Neumunaitis J, Shannon-Dorcy K, Appelbaum FR, Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993;82:1422-7
   PubMedGoogle Scholar
• BitMansour A, Cao TM, Chao S, Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia. Blood 2005;105:3535-7
   PubMed Web of Science ®Google Scholar
• Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2009;1:CD005341
   Google Scholar
• Seidel MG, Peters C, Wacker A, Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008;42:679-84
   PubMed Web of Science ®Google Scholar
• Stevens DA, Brummer E, Clemons KV. Interferon-gamma as an antifungal. J Infect Dis 2006;194(Suppl 1):S33-7
   PubMedGoogle Scholar
• Pappas PG, Bustamante B, Ticona E, Recombinant interferon – gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189:2185-91
   PubMed Web of Science ®Google Scholar
• Netea MG, Ferwerda G, van der Graaf CA, Recognition of fungal pathogens by toll-like receptors. Curr Pharm Des 2006;12:4195-201
   PubMed Web of Science ®Google Scholar
• Netea MG, Van Der Graaf CA, Vonk AG, The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002;185:1483-9
   PubMed Web of Science ®Google Scholar
• Ferwerda B, Ferwerda G, Plantinga TS, Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009;361:1760-7
   PubMed Web of Science ®Google Scholar
• Bochud PY, Chien JW, Marr KA, Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-77
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Gaziano R, Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-9
   PubMed Web of Science ®Google Scholar
• Gaziano R, Bozza S, Bellocchio S, Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004;48:4414-21
   PubMed Web of Science ®Google Scholar
• Larsen RA, Pappas PG, Perfect J, Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005;49:952-8
   PubMed Web of Science ®Google Scholar
• Martinez LR, Christaki E, Casadevall A. Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro. J Infect Dis 2006;194:261-6
   PubMed Web of Science ®Google Scholar
• Rachini A, Pietrella D, Lupo P, An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 2007;75:5085-94
   PubMed Web of Science ®Google Scholar
• Pachl J, Svoboda P, Jacobs F, A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006;42:1404-13
   PubMed Web of Science ®Google Scholar
• Nooney L, Matthews RC, Burnie JP. Evaluation of mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis 2005;51:19-29
   PubMed Web of Science ®Google Scholar
• Cowen LE, Singh SD, Kohler JR, Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009;106:2818-23
   PubMed Web of Science ®Google Scholar
• Singh SD, Robbins N, Zaas AK, Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 2009;5:e1000532
   PubMed Web of Science ®Google Scholar
• Torosantucci A, Bromuro C, Chiani P, A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005;202:597-606
   PubMed Web of Science ®Google Scholar
• Pirofski LA, Casadevall A. Immunomodulators as an antimicrobial tool. Curr Opin Microbiol 2006;9:489-95
   PubMed Web of Science ®Google Scholar
• French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-27
   PubMed Web of Science ®Google Scholar
• Robertson J, Meier M, Wall J, Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639-46
   PubMed Web of Science ®Google Scholar
• Miceli MH, Maertens J, Buve K, Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007;110:112-20
   PubMed Web of Science ®Google Scholar
• Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis (discussion 31-2). Surg Neurol 2005;63:529-31
   PubMedGoogle Scholar
• Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006;20:679-97
   PubMed Web of Science ®Google Scholar
• Sun HY, Alexander BD, Lortholary O, Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009;49:1721-8
   PubMed Web of Science ®Google Scholar
• Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008;30:167-72
   PubMed Web of Science ®Google Scholar
• Armstrong-James D. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J Antimicrob Chemother 2007;60:459-60
   PubMed Web of Science ®Google Scholar
• Arnold HM, Micek St, Shorr AF, Hospital resource utilization and cost of inappropriate treatment of candidemia. Pharmacotherapy 2010;20:361-8
   Google Scholar
• Arnold HM, Micek St, Shorr AF, Hospital resource utilization and cost of inappropriate treatment of candidemia. Pharmacotherapy 2010;20:361-8
   Google Scholar
• Hsu DI, Nguyen M, Nguyen L, A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010;65:1765-70
   PubMed Web of Science ®Google Scholar
• Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008;36:2967-72
   PubMed Web of Science ®Google Scholar
• Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007;60:613-18
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Kollef MH, Arnold H, Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010;10:150
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010;53:95-113
   PubMed Web of Science ®Google Scholar
• Vu K, Gelli A. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. Med Mycol 2010;48:255-62
   PubMed Web of Science ®Google Scholar
• Blankenship JR, Steinbach WJ, Perfect JR, Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investing Drugs 2003;4:192-9
   PubMedGoogle Scholar